Guoju Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guoju Dong has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Chenguang Yang
Department of Cardiovascular Internal Medicine, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, China
6 shared publicationsChunqiu Liu
Department of Cardiovascular Internal Medicine, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, China
6 shared publicationsSiyu Liu
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
6 shared publicationsWenbo Qiao
Department of Cardiovascular Internal Medicine, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, China
5 shared publicationsYujiao Shi
Department of Cardiovascular Internal Medicine, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, China
5 shared publicationsZiyi Chen
National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China
5 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in Scientific Reports
Platelet to white blood cell ratio and short term mortality in critically ill patients with HFpEF
- 21 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessPlatelet to white blood cell ratio and short term mortality in critically ill patients with HFpEF
- Open Access
- 16 May 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 369, 121872
LingGui QiHua-3 decoction (LGQH-3) ameliorates cardiorenal dysfunction in HFpEF by restoring fluid homeostasis via the PCSK6/Corin/p38 MAPK/AQPs axis
- 16 May 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 369, 121872
Open AccessLingGui QiHua-3 decoction (LGQH-3) ameliorates cardiorenal dysfunction in HFpEF by restoring fluid homeostasis via the PCSK6/Corin/p38 MAPK/AQPs axis
- Open Access
- 21 March 2026
- Published by Elsevier in Phytomedicine
- Vol. 155, 158099
Mahuang decoction targets fluid retention in heart failure with preserved ejection fraction
- 21 March 2026
- Published by Elsevier in Phytomedicine
- Vol. 155, 158099
Open AccessMahuang decoction targets fluid retention in heart failure with preserved ejection fraction
- Open Access
- 15 March 2026
- Published by Elsevier in The Journal of Physiological Sciences
- Vol. 76 (2) , 100068
Sweat components as a promising monitoring tool for systemic diseases
- 15 March 2026
- Published by Elsevier in The Journal of Physiological Sciences
- Vol. 76 (2) , 100068
Open AccessSweat components as a promising monitoring tool for systemic diseases
- Top Cited Papers
- 7 January 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 209, 106267
Association between the platelet to white blood cell ratio and short term mortality in critically ill patients with atherosclerotic cardiovascular disease: A retrospective study and machine learning with external validation
- 7 January 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 209, 106267
Top Cited PapersAssociation between the platelet to white blood cell ratio and short term mortality in critically ill patients with atherosclerotic cardiovascular disease: A retrospective study and machine learning with external validation
- Open Access
- 21 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1652307
Prediction models and risk scores in different types of heart failure: a review
Background: Heart failure (HF) is a leading cause of global disease burden and mortality. Accurate prognosis assessment is critical for reducing the risk of adverse events. In recent years, numerous predictive models have been developed for different HF subtypes. However, the quality of existing models varies considerably, and there remains a lack of consensus on models suitable for widespread clinical application. This study systematically reviews the current landscape of HF prediction models, analyzes their strengths and limitations, and provides guidance for future research. Methods: This review systematically retrieved studies on prognostic prediction models for HF from databases including PubMed and Embase, with a search period spanning from the inception of each database to 19 September 2025. The risk of bias of the included studies was assessed using the prediction model risk of bias assessment tool, and the performance of the prediction models was evaluated through metrics such as the C-index and calibration. Results: A total of 46 prediction models from 38 studies were included. According to target population classification, 14 models were developed for predicting outcomes in HF patients with reduced ejection fraction, nine models were applicable to HF patients with preserved ejection fraction, one model targeted HF patients with mildly reduced ejection fraction, and the remaining 22 were designed for all HF patients regardless of subtype. The risk of bias assessment showed that 10 models had a high risk of bias, 21 models demonstrated an unclear risk of bias, and 15 models exhibited a low risk of bias. The study systematically summarized each model's study cohort, modeling methodology, predictors, outcomes, prediction performance, presentation format, as well as strengths and limitations. Conclusion: Refining the methodological processes of model construction—including optimizing study cohort selection, updating predictor screening (such as incorporating novel biomarkers, imaging indicators, and multi-omics data), improving modeling strategies, and enhancing model presentation—will contribute to the development of more accurate and clinically applicable prediction models. Such advancements hold significant potential for improving clinical outcomes in patients across all types of HF. This review provides a substantive reference for future research in this field.
- 21 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1652307
Open AccessPrediction models and risk scores in different types of heart failure: a review
Background: Heart failure (HF) is a leading cause of global disease burden and mortality. Accurate prognosis assessment is critical for reducing the risk of adverse events. In recent years, numerous predictive models have been developed for different HF subtypes. However, the quality of existing models varies considerably, and there remains a lack of consensus on models suitable for widespread clinical application. This study systematically reviews the current landscape of HF prediction models, analyzes their strengths and limitations, and provides guidance for future research. Methods: This review systematically retrieved studies on prognostic prediction models for HF from databases including PubMed and Embase, with a search period spanning from the inception of each database to 19 September 2025. The risk of bias of the included studies was assessed using the prediction model risk of bias assessment tool, and the performance of the prediction models was evaluated through metrics such as the C-index and calibration. Results: A total of 46 prediction models from 38 studies were included. According to target population classification, 14 models were developed for predicting outcomes in HF patients with reduced ejection fraction, nine models were applicable to HF patients with preserved ejection fraction, one model targeted HF patients with mildly reduced ejection fraction, and the remaining 22 were designed for all HF patients regardless of subtype. The risk of bias assessment showed that 10 models had a high risk of bias, 21 models demonstrated an unclear risk of bias, and 15 models exhibited a low risk of bias. The study systematically summarized each model's study cohort, modeling methodology, predictors, outcomes, prediction performance, presentation format, as well as strengths and limitations. Conclusion: Refining the methodological processes of model construction—including optimizing study cohort selection, updating predictor screening (such as incorporating novel biomarkers, imaging indicators, and multi-omics data), improving modeling strategies, and enhancing model presentation—will contribute to the development of more accurate and clinically applicable prediction models. Such advancements hold significant potential for improving clinical outcomes in patients across all types of HF. This review provides a substantive reference for future research in this field.
- Open Access
- 7 November 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 961, 176170
Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction
- 7 November 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 961, 176170
Open AccessSacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction
- Open Access
- 25 September 2023
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 24 (9) , 274
Development and Challenges of Pre-Heart Failure with Preserved Ejection Fraction
Pre-heart failure with preserved ejection fraction (Pre-HFpEF) is a critical link to the development of heart failure with preserved ejection fraction (HFpEF). Early recognition and early intervention of pre-HFpEF will halt the progression of HFpEF. This article addresses the concept proposal, development, and evolution of pre-HFpEF, the mechanisms and risks of pre-HFpEF, the screening methods to recognize pre-HFpEF, and the treatment of pre-HFpEF. Despite the challenges, we believe more focus on the topic will resolve more problems.
- 25 September 2023
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 24 (9) , 274
Open AccessDevelopment and Challenges of Pre-Heart Failure with Preserved Ejection Fraction
Pre-heart failure with preserved ejection fraction (Pre-HFpEF) is a critical link to the development of heart failure with preserved ejection fraction (HFpEF). Early recognition and early intervention of pre-HFpEF will halt the progression of HFpEF. This article addresses the concept proposal, development, and evolution of pre-HFpEF, the mechanisms and risks of pre-HFpEF, the screening methods to recognize pre-HFpEF, and the treatment of pre-HFpEF. Despite the challenges, we believe more focus on the topic will resolve more problems.
- Open Access
- 4 July 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1208370
A rat model of metabolic syndrome-related heart failure with preserved ejection fraction phenotype: pathological alterations and possible molecular mechanisms
Background: Heart failure with preserved ejection fraction (HFpEF) represents a syndrome involving multiple pathophysiologic disorders and clinical phenotypes. This complexity makes it challenging to develop a comprehensive preclinical model, which presents an obstacle to elucidating disease mechanisms and developing new drugs. Metabolic syndrome (MetS) is a major phenotype of HFpEF. Thus, we produced a rat model of the MetS-related HFpEF phenotype and explored the molecular mechanisms underpinning the observed pathological changes.Methods: A rat model of the MetS-related HFpEF phenotype was created by feeding spontaneously hypertensive rats a high-fat-salt-sugar diet and administering streptozotocin solution intraperitoneally. Subsequently, pathological changes in the rat heart and their possible molecular mechanisms were explored.Results: The HFpEF rats demonstrated primary features of MetS, such as hypertension, hyperglycemia, hyperlipidemia, insulin resistance, and cardiac anomalies, such as left ventricular (LV) remodeling and diastolic impairment, and left atrial dilation. Additionally, inflammation, myocardial hypertrophy, and fibrosis were observed in LV myocardial tissue, which may be associated with diverse cellular and molecular signaling cascades. First, the inflammatory response might be related to the overexpression of inflammatory regulators (growth differentiation factor 15 (GDF-15), intercellular adhesion molecule-1 (ICAM-1), and vascular endothelial cell adhesion molecule-1 (VCAM-1)). Secondly, phosphorylated glycogen synthase kinase 3β (GSK-3β) may stimulate cardiac hypertrophy, which was regulated by activated -RAC-alpha serine/threonine-protein kinase (AKT). Finally, the transforming growth factor-β1 (TGF-β1)/Smads pathway might regulate collagen production and fibroblast activation, promoting myocardial fibrosis.Conclusion: The HFpEF rat replicates the pathology and clinical presentation of human HFpEF with MetS and may be a reliable preclinical model that helps elucidate HFpEF pathogenesis and develop effective treatment strategies.
- 4 July 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1208370
Open AccessA rat model of metabolic syndrome-related heart failure with preserved ejection fraction phenotype: pathological alterations and possible molecular mechanisms
Background: Heart failure with preserved ejection fraction (HFpEF) represents a syndrome involving multiple pathophysiologic disorders and clinical phenotypes. This complexity makes it challenging to develop a comprehensive preclinical model, which presents an obstacle to elucidating disease mechanisms and developing new drugs. Metabolic syndrome (MetS) is a major phenotype of HFpEF. Thus, we produced a rat model of the MetS-related HFpEF phenotype and explored the molecular mechanisms underpinning the observed pathological changes.Methods: A rat model of the MetS-related HFpEF phenotype was created by feeding spontaneously hypertensive rats a high-fat-salt-sugar diet and administering streptozotocin solution intraperitoneally. Subsequently, pathological changes in the rat heart and their possible molecular mechanisms were explored.Results: The HFpEF rats demonstrated primary features of MetS, such as hypertension, hyperglycemia, hyperlipidemia, insulin resistance, and cardiac anomalies, such as left ventricular (LV) remodeling and diastolic impairment, and left atrial dilation. Additionally, inflammation, myocardial hypertrophy, and fibrosis were observed in LV myocardial tissue, which may be associated with diverse cellular and molecular signaling cascades. First, the inflammatory response might be related to the overexpression of inflammatory regulators (growth differentiation factor 15 (GDF-15), intercellular adhesion molecule-1 (ICAM-1), and vascular endothelial cell adhesion molecule-1 (VCAM-1)). Secondly, phosphorylated glycogen synthase kinase 3β (GSK-3β) may stimulate cardiac hypertrophy, which was regulated by activated -RAC-alpha serine/threonine-protein kinase (AKT). Finally, the transforming growth factor-β1 (TGF-β1)/Smads pathway might regulate collagen production and fibroblast activation, promoting myocardial fibrosis.Conclusion: The HFpEF rat replicates the pathology and clinical presentation of human HFpEF with MetS and may be a reliable preclinical model that helps elucidate HFpEF pathogenesis and develop effective treatment strategies.